⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
Medincell participera aux conférences investisseurs Leerink et Jefferies à Miami, du 8 au 11 mars 2026
businesswire.com
TEVA
Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
businesswire.com
TEVA
LexisNexis Recognizes Visionary Companies From 18 Countries as “Top 100 Global Innovators” for 2026
globenewswire.com
IBM
ADI
AMAT
AVGO
CDNS
CSCO
DELL
GOOG
INTC
MRVL
MSFT
NVDA
QCOM
AMD
TXN
ADPT
LRCX
MU
SNPS
AMGN
BMY
GILD
LLY
MRK
PFE
REGN
TEVA
VRTX
ACGL
DOW
ECL
HON
LMT
MMM
NEE
RTX
UNH
XOM
INTU
MCHP
IP
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
globenewswire.com
TEVA
7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
globenewswire.com
SNY
REGN
AMGN
AZN
GSK
NVS
TEVA
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036
globenewswire.com
ABBV
ALC
APLS
BHC
JNJ
PFE
REGN
TEVA
VTRS
Teva to Present at the Upcoming Investor Conferences in March
globenewswire.com
TEVA
Medincell to Present at the TD Cowen 46 th Annual Healthcare Conference in Boston, March 2-4, 2026
businesswire.com
TEVA
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
businesswire.com
TEVA
Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI
businesswire.com
TEVA